News - Impala Nordic

Seamless Distribution Systems - Coverage comment

2026-04-08

Impala Nordic comments on the news that Seamless Distribution Systems has secured yet another order linked to upgrades of its core ERS platform. The most recent order of SEK 5 million increases SDS’ communicated secured EBT for 2026 to over 40 % of the full-year guidance of SEK 45-55 million.

Impala Nordic publishes equity analysis on Seamless Distribution Systems AB (publ)

2026-03-30

SDS is a global provider of mission-critical sales and distribution (S&D) software systems for telecom operators, mainly in emerging markets. The Company’s core proposition is to digitize prepaid mobile credit for calls and data (airtime), and adjacent telecom retail flows, replacing physically distributed vouchers and manual reseller processes with real-time systems.

Seamless Distribution Systems - Coverage comment

2026-03-10

Impala Nordic comments on recent updates from Seamless Distribution Systems, where the company has announced several orders early in 2026 linked to upgrades of its core ERS platform. Today’s order of SEK 4 million increases the Company’s “secured” earnings before tax (EBT) for 2026 to SEK 18-20 million. This corresponds to approximately 40 % of SDS’ full-year guidance of SEK 45-55 million.

Teaser Analysis – Seamless Distribution Systems

2026-03-05

Impala Nordic initiates coverage on Seamless Distribution Systems and publishes a teaser analysis. SDS is a global provider of sales and distribution software systems for telecom operators, primarily in emerging markets. The Company’s solutions digitize prepaid mobile credit for calls and data, replacing physical vouchers and manual reseller processes with real-time systems that improve revenue oversight and streamline telecom retail distribution.

OncoZenge - Report comment

2026-03-02

Impala Nordic comments on OncoZenge year-end report. The report positions the case firmly around the upcoming pivotal Phase III study. With the Clinical Trial Application (CTA) submitted in December 2025, the company expects an approval decision in the second half of April or early May and reiterates its ambition to dose the first patient in Q2 2026.

OncoZenge - Coverage comment

2026-02-03

Impala Nordic comments on OncoZenge latest news, including the appointment of Dr. Marie-Louise Fjällskog as Chief Medical Officer (CMO) and the positive one-month stability results for the BupiZenge™ technology batch. The news supports operational readiness as the Company moves into the execution phase ahead of the planned Phase III trial targeting first patient in Q2 2026.

Q&A with OncoZenge AB (publ) with CEO, Stian Kildal

2026-01-23

Impala Nordic has interviewed Stian Kildal, CEO of OncoZenge, about the recent development of a delayed tranche 3 payment from the company’s strategic investor and the bridge solution implemented to secure short-term liquidity until the proceeds are received. The Q&A also covers the background of the delay and whether the situation impacts ongoing Phase III preparation activities for BupiZenge, including the current Clinical Trial Application (CTA) process.

OncoZenge – Coverage comment

2025-12-23

Impala Nordic comments on the news that OncoZenge has submitted the Clinical Trial Application (CTA) for its pivotal European Phase III study of BupiZengeTM. The submission also triggered a 9.1 MSEK funding tranche under the existing investment agreement with Sichuan Yangtian Bio-Pharmaceutical Ltd. We view this as a critical step that sets the Phase III program in motion.

2025-12-05

Transfer Group - Interview with Mats Holmberg and Mathias Svedlund

See video

2025-12-04

OncoZenge Coverage Commentary - Execution enhanced through expanded Molteni partnership

Impala Nordic comments on OncoZenge latest news regarding the expanded agreement with its strategic partner Molteni. Under the agreement, Molteni assumes responsibility for high-volume, commercial-scale manufacturing of BupiZenge for the European market.

2025-11-21

Brain+ Coverage Commentary - Guidance cut, timing delays intensify

Impala Nordic comments on Brain+ updated guidance for 2025. Management adjusts all top-line and cash metrics for the year and widens the net loss, citing longer sales and deployment cycles in the UK care-home market.

Simultaneously pointing to operational progress with more providers live, trained staff, strong feedback, and commitments into 2026. The guidance cut is consistent with the risks we’ve flagged for in previous comments related to timing and revenue deferral, but the scale is larger than we anticipated at H1. The updated guidance confirms that timing is the binding constraint in 2025, and raises the bar on execution in 2026.

2025-11-11

Report comment Carbiotix - Commercialization takes shape, two JCDAs after the quarter

Impala Nordic comments on Carbiotix's quarterly report for the third quarter of 2025. The company presents a quarter with continued building of commercial conditions and a more controlled cost picture. After the end of the quarter, the company has also signed two NutraCycle Joint Commercial Development Agreements with two world-leading producers. Our overall view is that the investment case remains and that conversion to license and operation will be a crucial step in 2026.

2025-11-07

Five Quick Questions with Transfer Group

Mats Holmberg, CEO of Transfer Group AB (publ), answers five quick questions about the two most recently announced procurements, totaling approximately SEK 1.2 billion.

2025-11-05

Carbiotix - Signs first JCDA agreement with global wine producer

Impala Nordic is commenting on the news that Carbiotix has entered into a JCDA for NutraCycle with one of the world's largest wine producers. The agreement marks the transition from feasibility study to validation in a customer environment with a view to licensing and operation, and is the first of five JCDAs that the Company aims to enter into before the end of the year.

2025-10-28

Teaser analysis - Northern Capsek Ventures AB

Impala Nordic begins coverage of Northern Capsek Ventures AB (“CapSek” or the “Company”) and publishes a teaser analysis. CapSek is an investment company that invests in fast-growing tech companies in Swedish growth regions. The company focuses on companies in the scale-up phase, with an emphasis on software companies.

2025-10-28

Coverage comment Prebona – Commercial acceleration in the textile market

Impala Nordic comments that Prebona AB (“Prebona” or the “Company”) continues to convert collaborations in the textile market into deals during H2 2025. This is considered an important step from market access to execution, and that investments in the sales organization are starting to yield results.

2025-10-21

The Hot Chair - Northern Capsek Ventures

Henrik Jerner, CEO of Northern CapSek Ventures AB, talks about the company's ongoing process regarding a potential merger with portfolio company Arctic Space Technologies. Henrik also comments on the rights issue that begins today, October 21 and runs until November 4, focusing on how the net proceeds are intended to create financial space for the structural deal, while also enabling selective additional investments and increased ownership in promising portfolio companies.

Finally, important milestones and triggers are touched upon, including paths forward for CapSek regardless of whether the deal with Arctic Space Technologies is completed or not.

2025-10-01

Coverage comment Lappland Guldprospektering - Found record levels of gold in Stortjärnhobben

Impala Nordic comments that Lappland Guldprospektering has found record levels of gold in its drill program in Stortjärnhobben. The company has completed 16 drill holes in the ongoing drill program and received analysis results from seven of these. We consider the results to be very encouraging, with a superior record of gold grade in the most gold-rich section.

2025-09-24

Brain+ Coverage Commentary - Launches first NHS pilot in UK primary care

Impala Nordic comments the news that Brain+ has signed an agreement to deploy the Company’s Cognitive Stimulation Therapy (“CST”) Assistant, Ayla, in one of the UK’s largest primary care practices within the UK National Health Service (“NHS”). We view this agreement as a landmark step for Ayla’s UK adoption.

2025-09-24

Charlie Dahlström - Stock analyst

Charlie holds a Master's degree in Accounting & Finance with a specialization in Corporate Finance from the School of Economics and Business Administration at Lund University. During his studies, he has completed several internships in the financial industry, most recently from Eminova Partners Corporate Finance.

2025-09-11

OncoZenge Coverage Commentary - Has appointed LINK Medical as CRO for the upcoming European Phase III study of BupiZenge™

Impala Nordic comments on the news that OncoZenge has appointed LINK Medical as CRO for its upcoming European Phase III study of BupiZenge™.

Following a successful feasibility study of LINK, we are positive about the appointment and selection of clinics in the Nordics and Germany, in line with the previously communicated plan and timeline.

2025-09-03

Report comment Brain+ - Strategy on track, revenue defers into 2026

Impala Nordic comments on the half-year report for H1 2025. The report is broadly in line with expectations, showing continued progress in UK private care homes. The company maintains its target of operational cash-flow break-even by mid-2026 and expects to achieve at least DKK 3.6m in contracted sales.

However, the expected realized cash flow from sales in 2025 has been adjusted to DKK 3.0m due to longer cycles from contracting to invoicing. On 2 September 2025, Brain+ expanded its agreement with Southcare to include three additional homes, further strengthening scalability in the UK, which we consider central to the investment case.

2025-08-21

Report comment OncoZenge - Preparations for phase 3 study in focus

Impala Nordic comments on OncoZenge's quarterly report for the second quarter of 2025. OncoZenge presents a report in line with our expectations, where the focus remains on preparations for the phase 3 study, which is expected to begin in the first half of 2026.

2025-08-20

FinVoices: Mats Holmberg, CEO of Transfer Group, and Mathias Svedlund, CEO of Sensec Solutions.

Mats Holmberg, CEO of Transfer Group, and Mathias Svedlund, CEO of Sensec Solutions, share the company's business model, customer base and ongoing sales process. They also talk about how a sale can strengthen Transfer Group's financial position.

Listen to the Podcast

2025-08-12

Research comment Carbiotix – Conducts directed share issue

Impala Nordic comments that Carbiotix has resolved on a directed share issue, providing the Company with approximately SEK 2.8 million after transaction costs.

We view it positively that existing shareholders choose to continue supporting the Company, while the issue is conducted in a shareholder-friendly manner.

2025-08-12

Impala Nordic publishes equity analysis on OncoZenge AB (publ)

Impala Nordic has published an updated equity research report on OncoZenge, where we present our view on the Company’s recent developments.

OncoZenge is a Swedish research company developing BupiZenge™, a pain-relieving lozenge intended for the treatment of oral mucositis. The Company plans to conduct a European Phase 3 trial, which will form the basis for marketing authorisation of BupiZenge™ in Europe.

Read the company analysis

2025-08-05

Report comment Carbiotix – Project portfolio in focus

Impala Nordic comments on Carbiotix’s Q2 2025 report, which showed figures in line with the previous quarter. Operating expenses amounted to approximately SEK 4.3 million.

We note that the Company is in need of additional capital and assess that a directed share issue will likely be announced shortly. The focus remains on generating JDA projects and licensing agreements from the existing project portfolio, which we consider central to the investment case.

2025-07-25

Hot chair – Transfer Group

Mats Holmberg, CEO of Transfer Group AB (publ), discusses the Company’s ongoing divestment processes for the subsidiaries Sensec AB and Amigo Systems AB, as well as the strategy going forward for the remaining subsidiaries.

Mats also provides an outlook on the valuation expected from the sale of Sensec and the potential for a shareholder dividend. Finally, the discussion touches upon the order intake in Transfer Group’s subsidiaries and the outlook for Altum Security AB and Safe AB.

2025-07-21

Report comment DUG Foodtech - Strong growth and increased sales efforts

Impala Nordic comments on DUG Foodtech's report for the second quarter of 2025, which showed strong organic sales growth.

Net sales amounted to 1,862 thousand SEK, which corresponds to a growth of over 350% compared to Q2 2024. Compared to the first quarter of 2025, net sales increased by a whopping 44 %, which is considered strong.

2025-06-27

Coverage Commentary Lappland Gold Prospecting - Green light to take over Stortjärnhobben

Impala Nordic comments on the news that Lappland Gold Prospecting has received a decision from the Land and Environmental Court that the Company is granted access to the land at Stortjärnhobben.

Impala Nordic sees the decision as a positive imprint on the Company's project, given that a regulatory obstacle has been removed.

2025-06-25

Impala Nordic publishes equity analysis on Brain+ A/S

Impala Nordic initiates coverage on Brain+, a pioneering Danish life-science company digital solutions for improved dementia care, helping people affected by dementia live better lives.

The Company is developing Ayla, the world's first dementia-care platform, aiming to reach operational break even by mid 2026.

2025-06-24

Impala Nordic publishes analysis on ChargePanel AB (publ)

Impala Nordic releases an updated analysis of ChargePanel AB as a result of the Company's recent successes.

Including the agreements with Eways and Arval, which are expected to contribute annual revenues in the million range.

2025-06-12

Prebona coverage comment - Sharpens sales opportunities - Distribution agreement in Asia and key competence in place

Impala Nordic comments on the news that Prebona has entered into a distribution agreement with a leading player in Asia.

At the same time, the Company has strengthened its sales organization by recruiting key competence. Both the agreement and the recruitment increase Prebona's sales opportunities through access to an extensive distribution network.

2025-06-12

Coverage Comment ChargePanel - Agreement with Arval increases recurring revenue significantly

Impala Nordic comments on the news that ChargePanel has entered into an agreement with Arval, a subsidiary of BNP Parbias.

To offer a complete solution for electric vehicle charging to Arval's leasing customers in Sweden. The agreement is expected to significantly increase recurring revenue.

2025-06-11

DUG Foodtech Coverage Comment - Expanded store listing strengthens growth prospects

Impala Nordic comments on the news that DUG Footech's one product, DUG Barista, will be available in 1,400 Rossmann stores around Poland from July.

The fact that DUG continues to secure significant store listings strengthens the thesis of high growth potential in the coming years.

2025-06-04

Impala Nordic publishes analysis on Lappland Guldprospektering AB (publ)

Impala Nordic has prepared a company analysis on Lappland Guldprospektering AB (publ).

Lappland Guldprospektering is a Swedish company active in gold prospecting with a focus on developing and conducting gold mining on a larger scale in Sweden and the rest of the Nordic region.

Read the company analysis

2025-05-27

Prebona Coverage Comment - A Quarter Below Expectations

Impala Nordic comments on Prebona's report for the first quarter, where net sales fell and losses increased compared to the previous year.

Delayed launches and high inventory levels negatively affected net sales in the quarter.

2025-05-27

FinVoices: Devika Wood, CEO at Brain+ A/S

In this episode, Brain+'s newly appointed CEO Devika Woods shares her background in digital health and her vision for the company's potential.

She explains how the Ayla platform delivers Cognitive Stimulation Therapy to improve memory and attention, and discusses the UK healthcare system and efforts to integrate Brain+'s CST solution.

Listen to podcast episodes

2025-05-15

Report Comment OncoZenge - Includes license agreement for GCC Region

Impala Nordic comments on OncoZenge's quarterly report for the first quarter of 2025.

The report, as expected, contained no surprises. The focus remains on securing the final regulatory approvals for the investment agreement with Yangtian Pharma, in order to initiate the phase 3 study of BupiZenge™.

2025-05-14

Report comment ChargePanel - Activities in Q1 set the stage for a strong 2025

Impala Nordic comments on ChargePanel's interim report for the first quarter of 2025, where net sales amounted to approximately SEK 2.2 million and operating profit to SEK -2.8 million.

Net sales were negatively affected by changed accounting procedures, which means that growth is not visible compared to the comparison period. In reality, net sales are growing by just over 15% compared to Q1 2024, and we assess that the activities the Company has carried out set the stage for a strong 2025.

2025-05-13

Impala Nordic initiates analysis monitoring at DUG Foodtech AB (publ)

Impala Nordic initiates analysis coverage of DUG Foodtech, a company that develops and sells alternative dairy products based on potatoes.

The main focus is on beverages, where the company's brand DUG offers an alternative to milk and other non-dairy-based beverages.

2025-05-08

Report Comment Carbiotix - Good cost control and focus on license agreements

Carbiotix has released its report for the first quarter of 2025 and continues to show good cost control.

In our assessment, the report contains no surprises, and the focus is still on securing license agreements.

2025-05-05

Watch commentary Diamyd Medical - Successful capital raising

Impala Nordic comments the outcome of the rights issue in Diamyd Medical AB and considers the result, which shows an oversubscription of 108 percent, to be very impressive.

The company will receive SEK 224 million before issue costs through the rights issue, which are considered low as the issue was carried out without any guarantee commitments. In addition, the company has carried out a directed new issue to selected investors of SEK 41.6 million, which further strengthens the cash position.

2025-04-22

Carbiotix Coverage Comment - Directed New Issue with Premium

Impala Nordic comments on the news that Carbiotix is conducting a directed new issue to existing shareholders of a maximum of SEK 4.64 million at a subscription price of SEK 10.

The subscription price corresponds to a premium of approximately 11.1 percent compared to the closing price of SEK 9 on April 15, 2025.

2025-04-17

Impala Nordic has prepared a summary of the investment case in Diamyd Medical AB (publ)

Diamyd Medical is a biotechnology company that develops precision medicine therapies for the prevention and treatment of autoimmune type 1 diabetes.

The Company is currently conducting a rights issue of SEK 208 million to secure capital for the early readout of the Company's phase 3 study DIAGNODE-3 in March 2026.

Read the investment case

2025-04-11

Coverage Comment OncoZenge - License agreement signed for the GCC region

Impala Nordic comments on the news that OncoZenge has entered into a license agreement with Avernus Pharma for BupiZenge™ in the GCC region, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates.

Anette Mattsson, Deputy CEO, and Lars Rambe, CEO

2025-04-10

FinVoices: Lars Rambe, CEO & Anette Mattsson, vice CEO of Hoi Publishing AB (publ)

Anette Mattsson, vice CEO, and Lars Rambe, CEO of Hoi Publishing, share the company's unique hybrid model – where literature meets media.

They talk about their backgrounds, the path to profitability and growth – both organically and through acquisitions – and share their vision for the future.

Listen to the podcast episode

2025-04-03

Coverage Commentary Hoi Publishing AB (publ) - Secures Financing through Rights Issue

Impala Nordic publishes a coverage commentary on Hoi Publishing AB (publ) due to the upcoming rights issue.

Impala Nordic gives its view on the case, where majority-owned Eleven Stories is particularly interesting. The Company's guidance for 2025 and the view on the current valuation are also commented on.

2025-04-01

Watch Comment Carbiotix - Strong Momentum

Impala Nordic comments Carbiotix's latest quarterly update on its customer projects for the NutraCycle service.

Carbiotix now has a total of 47 customer projects, and the total number of side streams under evaluation is 58. The numbers speak for themselves - interest in NutraCycle is growing at a rapid pace.

2025-03-28

Hot chair - Hoi Publishing

Lars Rambe, CEO of Hoi Publishing, talks about the company's focus on film and television production, the potential of the acquisition of Eleven Stories and the launch of the new publishing imprint Lyrikhuset.

The company has identified four film projects that have a good chance of reaching full financing during the year, which would make a clear contribution to both turnover and results already 2025.

2025-03-28

Watch commentary OncoZenge - European partner secured and treasury strengthened

Impala Nordic comments on the news that OncoZenge has entered into a binding agreement with Molteni Farmaceutici.

Regarding exclusive rights and a commercial partnership to introduce BupiZenge™ in Europe.

2025-03-28

Coverage Comment Carbiotix - One Step Closer to Breakthrough

Impala Nordic comments on the news that Carbiotix has entered into a letter of intent (LOI) to sign a license agreement for NutraCycle.

The letter of intent takes Carbiotix one step closer to breakthrough and to go from being a promising company to becoming a growth company.

2025-03-26

Impala Nordic initiates analysis monitoring at Brain+ A/S and initiates with a teaser.

Brain+ is a Danish health tech company transforming dementia care by enabling scalable, high-quality solutions for health and care providers.

The Company is developing Ayla, the world's first dementia care platform for the scalable delivery of Cognitive Stimulation Therapy (CST), the leading non-pharmacological therapy for dementia.

2025-03-20

Impala Nordic initiates analysis coverage of Prebona AB (publ)

Impala Nordic initiates analysis coverage of Prebona AB (publ). Prebona is a company that develops environmentally friendly and functional products.

Among other things, for eliminating bad odors and surface coatings. Impala Nordic sees several exciting value drivers ahead, including expected cash flow positivity after the end of Q1.

2025-03-17

Hot chair - Brain+

We have interviewed Kim Baden-Kristensen, CEO of Brain+. Kim shares insights into the company's operations, strategy, and future outlook.

He also provides his perspective on the digital healthcare market and the key factors investors should keep an eye on in the coming years.

2025-03-11

ChargePanel coverage comment - Secures at least 5.8 MSEK through TO2

Impala Nordic comments on ChargePanel's latest announcement, where subscription commitments corresponding to 90% of TO2 secured.

The subscription price amounts to 1.01 SEK, which could raise 6.5 MSEK, of which at least 5.8 MSEK is secured. CEO Peter Persson is subscribing for shares for almost 1 MSEK, and TO2 is expected to significantly strengthen the company's cash position.

2025-03-10

Impala Nordic initiates analysis coverage of Adventure Box Technology AB (publ) and initiates with a teaser.

Adventure Box has recently completed the acquisition of the iGaming company Lion Gaming Group Inc. (“Lion Gaming”), and communicated several letters of intent regarding the acquisition of additional companies and assets within iGaming.

Through the acquisition of Lion Gaming, the Company is fundamentally changing, with both a new focus and stronger finances. Lion Gaming's estimated turnover was SEK 51.7 million for 2024 with an EBITDA result of SEK 2.3 million.

2025-02-25

Report Comment Chargepanel - Charging for record year

ChargePanels The Q4 report shows net sales of approximately SEK 2.6 million (2.4) with an operating profit of SEK -3.1 million (-4.3).

Overall, the company continues in the right direction, and adjusted for changes in accounting procedures, growth appears strong.

2025-02-20

Report commentary OncoZenge - An eventful quarter added to the files

OncoZenge reports continued good cost control with an operating profit of –2.5 MSEK and cash and cash equivalents of 3.9 MSEK.

In summary, 2025 will be an intense year for OncoZenge, where shareholders have several milestones to look forward to. Including the completion of the investment agreement with Yangtian and a finalized agreement with Molteni Farmaceutici.

2025-02-14

Carbiotix Coverage Comment - Aiming for License Agreement

Impala Nordic comments on Carbiotix's Q4 report, which contained no surprises. The cash was strengthened through a directed new share issue in January, but additional capital is likely needed by the summer.

The company reported a doubling of customer projects during Q4, where several collaborations are with companies with sales of over 10 billion USD.

2025-02-11

FinVoices: Christian Östberg, CEO at Prebona (publ)

Christian shares his background and what makes Prebona unique. He talks about the company's product portfolio, their collaborations and how the solutions can be used in different areas.

In addition, he touches on the financial goals and the ambition to achieve a positive cash flow after Q1 2025

Listen to the podcast episode

2025-02-10

Coverage Comment Diagonal Bio - Successful Capital Raising

Impala Nordic comments on the recent news flow and that Diagonal Bio has secured 6 MSEK net and received an order of 150,000 SEK

2025-02-03

Hot chair - Diagonal Bio

Karin Wehlin, CEO of Diagonal Bio, talks about the establishment in the horse segment, the increased business opportunities and the company's first order.

The company is currently conducting a rights issue where the capital will be used to commercialize LAMPlify® in the horse, pig and fish segments. The goal for 2025 is to deliver 40 platforms.

2025-01-31

Hot chair - OncoZenge

We have interviewed Stian Kildal, CEO of OncoZenge, who talks about the company's recent successes and the investment agreement with Yangtian Pharma.

The capital will be used to start the phase 3 study of BupiZenge™ and to strengthen OncoZenge's position in the global market.

2025-01-28

Coverage Commentary OncoZenge - Secures Financing for Phase 3 Study

Impala Nordic comments on the news that OncoZenge has entered into an investment agreement of 30.2 million SEK with Sichuan Yangtian Bio-Pharmaceutical.

The agreement secures financial resources to carry out the Company's European Phase 3 study.

2025-01-24

Coverage Comment Carbiotix - Strengthens the treasury through a directed new issue

Impala Nordic comments on the news that Carbiotix has carried out a directed new issue that raises approximately SEK 3.8 million after costs.

We view the news positively that Carbiotix once again demonstrates the ability to carry out an effective capital raising.

2025-01-16

Coverage Comment Chargepanel - Secures record-breaking contract worth 4.2 million SEK annually

Impala comments on the news that ChargePanel has signed an additional agreement with KG Knutsson AB, which includes 24,000 charging points at an annual value of 4.2 million SEK.

After the migration the number of charging points will increase from approximately 15,000 to 39,000.

2025-01-14

FinVoices: Christian Kronegård, CEO and Alexander Benitez, CCO of Kinda Brave AB (publ)

Christian and Alexander share the development of the game HELA, which has received over 22 million organic views.

They explain the reasons behind the decision not to communicate the launch date for the game title HELA, and provide insight into their financing strategy.

Listen to podcast episode

2025-01-14

Coverage Commentary OncoZenge - Intends to enter into agreements for commercialization in Europe

Impala comments on the news that OncoZenge has entered into a non-binding agreement with Molteni Farmaceutic for the commercialization of BupiZenge™ in Europe.

The goal is to sign a final license agreement by April 30, 2025.

2024-12-20

Hot chair - Zwipe

We have interviewed Robert Puskaric, CEO of Zwipe. Robert talks about the business, the ongoing rights issue and the strategy going forward.

He also shares his views on the biometrics market and what potential value drivers investors should keep an eye on in 2025.

2024-12-20

Carbiotix coverage comment - Strong growth of customer projects

Impala Nordic comments on Carbiotix's latest news about new customer projects, where the company added 16 new customer projects and entered into its first customer project in Asia.

The increase corresponds to a doubling, which means that the company now has a total of 32 ongoing customer projects and has surpassed Impala Nordic's base scenario in terms of customer projects.

2024-12-20

Impala Nordic initiates analysis coverage of DUG Foodtech AB (publ) and initiates with a teaser.

DUG is a Swedish foodtech company that develops plant-based foods based on potatoes.

2024-12-12

Impala Nordic initiates analysis coverage of Zwipe AS and initiates with a teaser

Zwipe AS is a Norwegian company founded in 2009 operating in biometrics.

The company develops and sells biometric cards, with a focus on the access management market.

2024-12-02

Impala Nordic publishes analysis on Carbiotix AB (publ)

Carbiotix is active in the extraction of prebiotics from plant-based side streams, proteins and other active ingredients.

The company is currently focusing on commercializing and out-licensing the up-cycling service NutraCycle.

Read the company analysis

2024-11-21

OncoZenge Coverage Comment - A Significant Setback

Impala comments on the news that the partnership between OncoZenge and Pharmanovia is not completed.

OncoZenge will now work to explore partnerships with other stakeholders.

2024-11-13

Chargepanel Coverage Comment - Strong growth YoY - seasonally weak quarter

ChargePanel shows strong growth in net sales YoY during Q3 2024, and is working towards achieving profitability on a monthly basis in 2025.

At the same time, the influx of new customers continues and the number of connected charging points is expected to reach 15,000 before the end of 2024.

2024-11-08

FinVoices: Jack Egelund Madsen, CEO for QNTM Labs

Jack Egelund Madsen shares insights about the business and its ambitious growth plans, highlighting one of QNTM's main goals for 2025, to increase revenue fivefold.

Listen to podcast episode

2024-11-08

ZingSec Coverage Comment - G2 Acquisition completes acquisition of ZignSec

Impala Nordic comments on the news that G2 Acquisition controls 94.6% of the shares in ZignSec. The bidder will complete the bid and thus also delist ZignSec.

2024-11-04

Impala Nordic initiates analysis coverage of Prebona AB (publ) and initiates with a teaser

Prebona is a materials technology company that delivers environmentally friendly and functional products within, among other things, the elimination of bad odors and surface coatings.

2024-10-28

Hot chair - DUG Foodtech

Helene Nielsen, CEO of DUG Foodtech, talks about the company's products and the transformation that has taken place in the business.

Helene also answers how the capital from the upcoming rights issue will be used, and what growth ambitions the company has.

2024-10-25

Impala Nordic initiates analysis coverage of Carbiotix AB (publ) and initiates with a teaser

Carbiotix operates in biotechnology and has developed an upcycling service that makes it possible for companies in, among others, the food and beverage industry to utilize plant-based side stream products.

2024-10-18

OncoZenge Coverage Comment - Partnership in Place

Impala Nordic comments on the news that OncoZenge intends to enter into a partnership with Pharmanovia for the commercialization of BupiZenge™.

The news is considered a major breakthrough and proves that there is a clear path to market.

2024-10-18

Hot chair - Prebona

In this interview, Christian Östberg, CEO of Prebona, talks about the company's focus on odor elimination and surface protection with their products OdorControl and DuraClean.

With patented and environmentally friendly technology, they aim to become cash flow positive in Q1 2025 and expand into markets such as Germany, North America and Asia.

2024-10-17

Hot chair - Kinda Brave

Christian Kronegård, CEO of Kinda Brave, highlights the investment in the game HELA, which is fully financed through an agreement with Knights Peak.

He also mentions the company's plans to expand into other media, such as TV and film, and to grow its portfolio of intellectual property rights.

2024-10-16

Hot chair - Tangiamo Touch Technology

In this interview, Christopher Steele, CEO at Tangiamo Touch Technology, shares insights on the acquisition of Trustplay and its significance for the company.

He also emphasizes the ongoing rights issue's importance for growth and transformation.

2024-10-11

FinVoices: Glenn Mac Donald, CEO, & Sergei Sergejev, product manager at ZignSec AB (publ)

Glenn Mac Donald, CEO, and Sergei Sergejev, product manager at ZignSec, discuss the Company's KYC and KYB solutions.

Glenn shares insights on ZignSec's growth strategy, client successes, and the recent public offering. Sergei explains how AI is transforming their products and meeting rising compliance demands in industries like cryptocurrency.

Listen to podcast episode

2024-10-11

Impala Nordic initiates analysis coverage of Tangiamo Touch Technology (publ) and initiates with a teaser

Tangiamo is a company operating in the gaming industry. The company specializes in physical gaming tables for casinos.

The company has recently broadened its operations to iGaming through the acquisition of Trustplay AB. The focus going forward is to grow within the iGaming sector and to work towards profitability. The upcoming rights issue will strengthen the Company's financial position and its potential for growth in the future.

2024-10-07

FinVoices: Christopher Steele, CEO of Tangiamo Touch Technology AB (publ)

Christopher provides insights into Tangiamo and discusses the company's expansion into the iGaming market through the acquisition of Trustplay.

He highlights Tangiamo's unique solutions, the integration of TrustPlay's products with existing offerings, key drivers for future growth, and the company's strategic goals for 2025.

Listen to podcast episode

2024-09-26

Watch comment: Chargepanel

ChargePanel has strengthened its cash flow and continues to work towards profitability. In the report for the second quarter of 2024, the Company reports stable revenue growth and reiterates the goal of profitability on a monthly basis in 2025.

2024-09-24

Hot chair - Hoi Publishing

In this interview, Lars Rambe, CEO of Hoi Publishing AB (publ), talks about the majority acquisition of the shares in Eleven Stories AB.

Furthermore, Rambe elaborates on the significance of the acquisition for the venture in mobile media, as well as the significant revenue opportunities going forward.

2024-09-18

FinVoices: Kristofer Cook, Co-founder of Carbiotix AB (publ)

Kristofer Cook, co-founder, chairman and Chief Business Development Officer at Carbiotix, shares insights into his entrepreneurial background and the journey of building Carbiotix.

We explore NutraCycle, the company's financial standing, competition, and team expansion.

Listen to podcast episode

2024-09-10

Hot chair - OncoZenge

Torben Mogensen, one of the co-inventors behind OncoZenge's drug candidate, BupiZenge™, shares insights into his background in anesthesiology and explains how the idea for BupiZenge™ was conceived.

Additionally, Mogensen discusses the medical need for patients suffering from oral mucositis and shares his hopes for the future of BupiZenge™.

2024-09-02

Coverage Comment - Hoi Publishing

Hoi Publishing is carrying out a major acquisition of 50.1% of the shares in the media company Eleven Stories AB and significantly improves growth opportunities.

Through the acquisition, Hoi becomes the majority owner of Eleven Stories AB, which is expected to increase Hoi's turnover will increase significantly in the coming years.

2024-08-26

Report Comment Hoi Publishing Q2 2024 – A Stable Quarter

Hoi Publishing AB (publ) has released its figures for the second quarter of 2024, where net sales amounted to 6.6 MSEK (4.2 MSEK).

We note that this corresponds to a growth of approximately 57% compared to Q2, while being in line with our expectation of approximately SEK 7 million.

2024-08-22

Report comment Q2 2024 - Good cost control

ZignSec AB (publ) has released the figures for the second quarter of 2024, which came in line with expectations.

The company reduces the loss significantly compared to Q2 2023 and returns to growth during the quarter.

2024-08-21

OncoZenge - Oral mucositis with Steph Gayhart

Steph Gayhart shares her personal experience with oral mucositis following head and neck cancer treatment.

Her story underscores the urgent need for better pain relief solutions and highlights the often-overlooked challenges that patients face.

Impala Nordic produced the video on behalf of OncoZenge AB (publ).

Watch video

2024-08-16

Hot chair - ZignSec

Daniel Grech, CTO of ZignSec, discussed how he leverages his background in Computer Science and Statistics in the development of KYC and KYB solutions at ZignSec.

Daniel outlines how ZignSec uses AI to automate compliance processes, ensuring both global scalability and adherence to regulatory requirements, while allowing experts to concentrate on high-risk cases. Daniel's approach ice to enhance efficiency and ensure security in digital identification.

2024-08-13

Report comment - OncoZenge

OncoZenge AB (publ) has released its quarterly report for the second quarter of 2024 and is in final negotiations with potential development partners. Impala Nordic comments on the quarterly report.

2024-08-13

FinVoices: Karin Wehlin, CEO of Diagonal Bio AB (publ)

Karin shares her journey from co-founder of EQL Pharma to CEO of Diagonal Bio.

She discusses the experiences from EQL Pharma and Respiratorius, as well as the company's CE-marked product LAMPlify® and plans for Panviral. The episode also discusses challenges and opportunities in the biotech and medtech sectors, Karin's view on the current stock market and financing climate for smaller companies, and strategies for securing capital.

Listen to podcast episode

2024-07-17

Impala Nordic visits Hunneberga Hästgård together with Diagonal Bio

Diagonal Bio visits Hunneberga Hästgård outside Lund to gain insight into how rapid diagnostics can improve horse healthcare.

During the visit, CEO Tomas Hammar and veterinarian Lisa Lidbeck talk about the importance of rapid diagnostics for competition horses. Karin Wehlin, CEO of Diagonal Bio, highlights the increasing demand for faster diagnostics in equestrian sports.

Watch video

2024-07-10

Impala Nordic initiates analysis monitoring at ZignSec AB (publ)

Impala Nordic starts analysis monitoring at ZignSec AB (publ). ZignSec is a prominent player in digital solutions for AML and KYC compliance.

The group, which consists of several companies, jointly offers a wide range of RegTech solutions. The company is listed on First North Stockholm.

2024-07-08

FinVoices: Ulf Hannelius, CEO of Diamyd Medical AB (publ)

Ulf shares his background in molecular biology and experience in the biotechnology industry, and provides an overview of Diamyd Medical.

Ulf discusses the progress of the DIAGNODE-3 study, the significance of the FDA Fast Track designation, and the benefits of intralymphatic immunotherapy. He also provides an update on the production facility in Umeå, the company's financing situation, and concludes by answering listener questions.

Listen to podcast episode

2024-07-08

Hot chair - PExA

Tomas Gustafsson, CEO of PExA AB (publ), describes how PExA is developing innovative instruments for non-invasive sampling of small airways in the lungs, which opens up new opportunities for research and diagnostics.

The company sells and rents its instruments globally and is now conducting a share issue of 7.4 MSEK to strengthen marketing and participate in international congresses. PExA market includes both research instruments and future diagnostics, with the potential to revolutionize the detection and treatment of lung diseases.

2024-06-07

Hot chair - ZignSec

Glenn Mac Donald, CEO of ZignSec, describes the Company's plan to use SEK 29 million from the latest rights issue to strengthen technology, marketing, and sales in Europe, Latin America, APAC, and Africa.

The funds will also be used to hire seniors salespeople and conduct targeted campaigns.

2024-06-03

Watch Commentary - Hoi Publishing

Hoi Publishing has increased net sales by 78.3% to SEK 4.4 million in Q1 2024 and improved EBITDA to SEK –0.05 million.

The growth is mainly due to the acquisitions of Superlux Aps and Ekström & Garay AB. Impala Nordic expects continued increased sales during Q2 and Q3, with forecasts of SEK 7 million and SEK 8.5 million, respectively.

2024-05-28

Svenska Dagbladet highlights Impala Nordic

In today's financial edition from Svenska Dagbladet, Impala Nordic has been highlighted through an article that highlights our modern holistic approach to Investor Relations.

Read article

2024-05-24

Watch Comment - ChargePanel

ChargePanel continues its expansion and recently announced that the Company has reached 10 000 connected charging points, an increase of 25% compared to the end of 2023.

The company thus continues its growth journey and the forecast is to reach 15,000 connected charging points before the end of 2024.

2024-05-20

Glenn Mac Donald, CEO of ZignSec, is interviewed by Impala Nordic

In the interview, Glenn talks about ZignSec's innovative KYC and KYB solutions within the RegTech sector.

He describes how the company generates revenue, the purpose of the new issue and strategies to stay competitive with new technology. He also highlights KYB solutions for payment processors and plans for future geographical expansion.

Watch the full video interview

2024-05-14

FinVoices: Chris Nowak on the project, the future and investments in life science

Christoph Nowak, MD, PhD, board member at OncoZenge AB (publ), shares his journey in the pharmaceutical and research industry.

The episode discusses the current treatment options for oral mucositis and why BupiZenge represents a significant advance in the field. We also take a look at Chris' other roles as Chief Medical and Business Officer at Diamyd Medical AB (publ) and Melius Pharma.

Listen to podcast episode

2024-04-23

Hot chair - Carbiotix

Erik Deaner, CEO of Carbiotix AB, discusses the company's work in microbiota research with its product Carbersol.

By providing high-quality soluble fibers for the dietary supplement industry, Carbiotix aims to combat the global shortage of fiber. The company strengthens its position through the NutraCycle service that converts waste products into valuable fibers, promoting a healthier diet and sustainable production.

2024-04-15

FinVoices: Lars Rambe, CEO of Hoi Publishing AB (publ)

Lars provides an overview of the Company's business operations, future plans and ongoing rights issue.

He also highlights the strategies that have contributed to the Company's impressive growth, including a turnover of 15.7 MSEK in 2023.

Listen to podcast episode

2024-04-11

Hot chair - PExA

Tomas Gustafsson, CEO of PExA AB (publ), highlights the company's unique technology that is changing lung research.

With an innovative instrument that enables the collection of samples from the lungs' small airways, Tomas shows how PExA opens up new opportunities for early detection and treatment of lung diseases. The company's customer base encompasses the global research community and ranges from studies related to the work environment to research on lung cancer.

2024-04-08

Impala Nordic publishes analysis on Hoi Publishing AB (publ)

Hoi Publishing is a fast-growing Nordic publishing group with a unique hybrid business model and a successful acquisition strategy.

Hoi Publishing is driving significant revenue growth and improved profitability. The company is listed on NGM.

2024-04-05

Watch Comment: OncoZenge

OncoZenge AB has reported positive stability data for BupiZenge™, which strengthens the possibility of further development and diversification of the product range.

This development underlines the potential for future product variants and confirms previous data. In parallel, the Company is exploring opportunities for partnerships in the Chinese market, with a focus on sales, clinical studies or licensing agreements.

Picture of some participants at the Investment Meeting

2024-04-04

Impala Invest investor meeting in Gothenburg

On March 21, Impala Invest organized an investor meeting in Gothenburg where Diagonal Bio AB, Hoi Publishing AB, PExA AB and Carbiotix AB presented.

The commitment from the investors was strong, which resulted in relevant questions and fruitful discussions.

Video interviews

2024-04-04

FinVoices: Glenn Mac Donald, CEO of ZignSec AB (publ)

Glenn shares his insights on ZignSecs adaptation to new rules and technologies within RegTech, as well as their strategies for global expansion and growth.

Here we also learn about ZignSec's future goals and visions, including the ambition to reach 20 million euros in net sales by 2027 to create shareholder value.

Listen to podcast episode

2024-03-27

Erik Deaner, CEO Carbiotix AB (publ), presents at Impala Invest's investor meeting

Watch video

2024-03-11

Impala Nordic initiates analysis coverage of HOI Publishing AB (publ) and begins with a teaser

HOI Publishing is a Swedish hybrid publisher with a digital focus and an ambitious acquisition agenda, which offers interesting growth opportunities.

The company's unique model, where the author and the publisher share the risk, creates good conditions for launching a large number of titles while limiting financial risk. Hoi ended 2023 with strong revenue growth and is completing a significant acquisition of the publisher Ekström & Garay and faces an exciting year ahead.

2024-03-08

Impala Nordic initiates analysis coverage on ZignSec AB (publ) and initiates with a teaser

ZignSec operates within RegTech, which includes various technical solutions for regulatory compliance.

ZignSec's digital solutions allow companies to meet regulatory requirements for Know Your Customer (KYC) and Anti-Money Laundering (AML) in real time. With a projected market for digital ID verification solutions of over USD 30 billion by 2024, ZignSec faces significant growth opportunities.

2024-03-06

Impala Nordic publishes analysis on Adverty AB (publ)

Adverty is a pioneer in In-Play advertising and has developed the world's first programmatic platform for automated advertising in mobile games.

The company has experienced impressive growth from 5 million SEK in 2021 to over 50 million SEK during 2023, with a positive operating profit reported for the fourth quarter of 2023. Adverty shows no signs of slowing down in growth, indicating a promising future for 2024.

2024-02-29

Hot chair - ZignSec

In this interview, ZignSec CEO Glenn Mac Donald highlights the company's position as a leader in the RegTech sector, specializing in identity verification and compliance with KYC and AML guidelines.

The business model is centered on providing efficient solutions for remote onboarding and due diligence. The company's future prospects are emphasized through a strategy focused on geographical expansion and investments in AI and LLM technologies to meet evolving market needs and drive growth.

2024-02-28

Watch Comment: OncoZenge

OncoZenge AB has received notification of PRIME status and released its year-end report for 2023. The company's application for PRIME status was not granted, but the announcement does not close the door to future applications or accelerated assessment from EMA.

At the same time, discussions are underway with potential partners for a phase 3 study, where dialogue is being held with three different actors. In February, OncoZenge also submitted a new patent application, which, if approved, could give BupiZenge™ market exclusivity until 2045.

2024-02-27

Impala Nordic visits Galenica together with OncoZenge

OncoZenge visits Galenica's team at Medeon Science Park to get an overview of the development of BupiZenge, a tablet intended for patients experiencing severe pain in the mouth, known as oral mucositis. The video has been prepared by Impala Nordic.

See full video interview

2024-02-26

The Hot Seat - Hoi Publishing

Lars Rambe, CEO of Hoi Publishing, shares his story of the transition from business lawyer to author - a journey that gave him valuable insights into the publishing industry and led to the creation of Hoi, the first publicly listed publisher in the Nordics.

Hoi Publishing aims to expand its operations and reach a turnover of over 200 million SEK within five years, initially in the Nordics and then globally. For 2024, the focus is on strengthening the synergies from its acquisitions, increasing turnover and generating profit.

2024-02-21

FinVoices: Stian Kildal, CEO, and Niclas Holmgren, board member and major owner of OncoZenge AB (publ)

OncoZenge's CEO, Stian Kildal, and major owner Niclas Holmgren discuss the company's development, strategies and future prospects.

They highlight how they have overcome previous challenges and their focus on meeting patient needs ahead of Phase 3. They also share insights on partnership plans and product positioning, and emphasize the company's goal of increasing transparency and trust among investors and stakeholders.

Watch podcast episode

2024-02-19

Coverage Comment: Diagonal Bio

Diagonal Bio AB has entered into a distribution agreement with Techtum Lab for the sale of LAMPlify® in Sweden, marking an important milestone in the product's commercialization.

Impala Nordic views the agreement positively, which is not only expected to generate revenue but also strengthen LAMPlify®'s market position.

2024-02-16

Hot Seat - Adverty

Jonas Söderqvist, CEO of Adverty, talks about the company's unique technology that offers brands an opportunity to reach players in an engaging and seamless way.

Jonas sees good growth prospects for Adverty, especially considering the ability to triple revenue annually and show profit at the EBITDA and EBT level. In 2024, the company will focus on increasing its growth within both advertisers and game publishers, as well as on launching new products.

2024-02-14

Impala Nordic initiates analysis monitoring at Adverty AB (publ) and initiates with a teaser

Adverty is at the forefront of ad technology with its unique, patent-protected in-play ads in mobile games.

Their technology enables seamless ads and has driven strong growth and profit in Q4 2023. With success in the US and Europe and clients such as Red Bull and Coca Cola, Adverty's leadership in a game advertising industry expected to reach $131 billion by 2025 is strengthened.

Man looking at his mobile phone and charging his electric car

2024-02-06

Coverage comment: ChargePanel AB

ChargePanel AB strengthens its market position and continues its journey towards profitability with a rights issue that is covered by 81% of subscription commitments and guarantee commitments, in which the board and management have actively participated.

The company also continues its global expansion with new customer agreements in Barbados and the Philippines and improves the connection process with the launch of the new service ConnectGO.

2024-02-06

Peter Persson, CEO of ChargePanel, is interviewed by Impala Nordic

In this video interview with Peter Persson, CEO of ChargePanel AB (publ), we get an overview of ChargePanel's operations and their customer base, unique position in the market, and the central drivers that make the company stand out.

Peter also talks about the key parts of ChargePanel's growth strategy, their international expansion, and how they generate revenue. Finally, the current issue and the use of the capital are highlighted.

Watch the full video interview

2024-01-16

Impala Nordic initiates analysis coverage of OncoZenge AB (publ)

OncoZenge is in an intensive phase of preparing BupiZenge for phase-3 studies and securing a study partner who can also promote a possible market launch in Europe.

Currently, OncoZenge is working to secure PRIME status with the EMA, which can facilitate the regulatory process. With a drug candidate that has the potential to improve the quality of life for people with oral mucositis, OncoZenge faces exciting future opportunities.

Hot chair - OncoZenge

Stian Kildal, CEO of OncoZenge, talks about the company's operations and their work to develop a lozenge for oral pain called "BupiZenge."

During the interview, OncoZenge's strategies for getting the product to market, the collaboration with Ensysce Biosciences, the expansion to international markets, financial aspects and the goals for the company in 2024.

2023-12-21

Impala Nordic starts analysis monitoring at ChargePanel AB (publ)

ChargePanel is focused on increasing the number of recurring revenues and connected charging points and is expected to increase its revenues and market share, especially with increased demand for charging infrastructure for electric vehicles.

Management's goal is to achieve profitability and positive cash flow by the end of 2024 which is a trigger for the case.

2023-12-19

FinVoices: Peter Persson, CEO ChargePanel AB (publ)

Peter shares his background and experience and provides an insight into ChargePanel.

The conversation covers various topics, including the company's growth strategy, customer flow, international presence and the increase in connected charging points in recent quarters. "We expect a 100% increase in the number of connected charging points year after year" - Peter Persson.

2023-12-11

FinVoices: Johanna Englundh, editor Morningstar

In today's episode we welcome Johanna Englundh, editor at Morningstar.

Who talks about the increasing ISK tax, why some savers try to time the market, the psychological factors behind investment decisions and concrete advice to avoid short-term decisions.

2023-12-11

Hot chair - Gabather

Michael-Robin Witt, CEO, enlightens potential partnerships based on preliminary study results of their drug candidate GT-002.

Witt highlighted plans for GT-002, aiming for development and commercialization post-Phase 2 studies, and concluded by outlining Gabather's main objectives for 2024. He also comments the ongoing rights issue where they raise SEK 28.6 million.

2023-12-08

Hot chair - Diagonal Bio

Karin Wehlin, interim CEO at Diagonal Bio, shares her extensive experience and talks about the company's progress, including the commercialization of its CE-marked product and plans for 2024.

She highlights challenges, emphasizes the company's attractive business model and market position.

2023-11-28

Coverage Comment: Diagonal Bio AB

Diagonal Bio AB continues to implement the stated strategy and begins the commercialization of LAMPlify™.

The company has also appointed Karin Wehlin as acting CEO after the board and the former CEO, Jack Egelund Madsen, jointly decided that Jack should resign.

2023-11-17

Impala Invest investor meeting in Malmö

On November 14th, Impala Invest organized an investor meeting in Malmö where Deversify AB, Diagonal Bio AB (publ) and Vibrosense Dynamics AB (publ) presented to investors.

A wonderful commitment and many wise questions were discussed.

2023-11-03

Watch Comment: Diagonal Bio AB

Diagonal Bio AB has made progress on its journey towards becoming a company with a commercialized product and is focusing on generating initial revenue through pilot tests.

2023-10-03

Compilation of the Annual Report for Goobit Group AB

We would like to thank Goobit Group for the trust they have shown us by entrusting us with preparing company's annual report May 1, 2022 - April 30, 2023.

We look forward to a continued fruitful partnership and exciting projects in the future in collaboration with Goobit Group.

Read the full annual report

2023-09-15

Hot chair - Diagonal Cinema

In this interview with Diagonal Bio, the CEO Jack Egelund Madsen gets further into Diagonal's strategic choices for 2023.

They've recently opted for a directed share issue and loan to strengthen the impact and focusing on the commercialization of LAMPlify™, recently CE-marked. Diagonal Bio aims to generate revenue and continue its innovative journey.

2023-09-01

Launch of Impala Invest

Impala Nordic has been around for almost a year and in the meantime we have built up a warm community and network of investors. Now you have the opportunity to join the network, Impala Invest.

Join Impala Invest

2023-08-17

We welcome our new star in Investor Relations, Melker Larsson

"We are pleased to welcome Melker to our Investor Relations team. Melker will play a key role in strengthening our relationships with investors and client companies and continue to drive Impala Nordic forward. Welcome aboard, Melker" - Ylber Rexhepi, CEO Impala Nordic

2023-07-25

Diagonal Bio has CE-marked LAMPlify - A promising future for the Company on the global market

Impala Nordics monitoring comment is published and can be read below.

2023-07-24

Impala Nordic initiates analysis monitoring at Diagonal Bio AB (publ)

Impala Nordic initiates analysis coverage at Diagonal Bio AB (publ).

The company has a strong pipeline ahead of it and aims to obtain CE marking for LAMPlify and then launch and commercialize its LAMPlify system for biomarker identification in 2023.

2023-07-05

The Hot Chair: Interview with Scandinavian Real Heart

Ina Laura Perkins, CEO of Scandinavian Real Heart, talks about the groundbreaking technology behind the company's artificial heart, the results from the pre-clinical studies and how Real Heart plans to invest the financing from the current new issue.

Ina also shares what the company has for plans ahead.

2023-07-05

Video interview with CEO of Scandinavian Real Heart AB, Ina Laura Perkins

Take part in an exciting video interview with Ina Laura Perkins, CEO of Scandinavian Real Heart and learn more about the company's artificial heart.

In this interview you will get to know the company Scandinavian Real Heart and the company's CEO, Ina Laura Perkins. You will also hear more about the pre-clinical studies, the current new share issue and Real Heart's future plans and visions.

Watch the full video interview

2023-06-29

FinVoices: The future of the housing market and successful revenue growth, with Jim Ankare, CEO of Samtrygg

In today's episode, we welcome Jim Ankare, CEO of Samtrygg, who talks about the company's business model, its role in the housing market and the potential for private rental to contribute to the circular economy and solve the housing shortage.

2023-06-26

Coverage Commentary: Blick Global Group and OMI gaming, certified game for global launch and strategic review.

Impala Nordic's coverage commentary has been published and can be read below.

2023-06-20

Film interview with CEO of Diagonal Bio AB, Jack Egelund Madsen

Take part in an exclusive interview with Jack Egelund Madsen, CEO of Diagonal Bio AB, where he describes Diagonal's groundbreaking biotech products, including LAMPlify and PANVIRAL.

Watch the full video interview

2023-06-19

Compilation of quarterly report, Goobit Group AB

We thank Goobit Group for the trust in assisting with the preparation of the company's latest quarterly report. We look forward to more fantastic projects together in the future.

Read the full report

2023-05-30

Coverage Comment: New Revenues after Launch and Certification of First Game via OMI

Impala Nordic's coverage comment for Blick Global Group has been published and can be read below.

2023-05-04

FinVoices: Jack Egelund Madsen about Diagonal Bio's external validation and upcoming milestones

In today's episode of FinVoices, we welcome Jack Egelund Madsen, CEO of Diagonal Bio. Jack shares the latest updates on the company's recent and upcoming milestones, and many other things.

2023-05-03

We are looking for an Investor Relations Sales

Investor Relations Sales wanted for fast-growing start-up within finance industry - Impala Nordic.

2023-04-27

Blick Q1 2023: Report Commentary from Impala Nordic

Impala Nordic's report commentary for Blick Global Group's first quarter 2023 is published and can be read below.

2023-04-26

FinVoices: Michaela Berglund on female entrepreneurship

In today's episode of FinVoices, we have the pleasure of welcoming Michaela Berglund, CEO of Feminvest, to discuss her journey into entrepreneurship and her successful acquisition of equity before moving on to active investing.

We also gain insight into how Feminvest supports female entrepreneurs and investors.

2023-04-13

Hot seat - Diagonal Bio AB

Jack Englund Madsen, CEO of Diagonal Bio AB tells us about the companies progress and about an external testing of Diagonal's patented technology made by an accredited laboratory.

Jack too answers questions about Diagonal's two technologies - LAMPlify™ and PANVIRAL™.

2023-04-11

Impala Nordic initiates analysis monitoring at Blick Global Group

Impala Nordic initiates analytical monitoring of Blick Global Group AB (publ). Blick Global Group aims to expand by acquiring 1-3 companies per year.

The company has shown an impressive annual revenue growth of 25% over the past three years and, supported by structural trends such as deregulation and digitalization, the company is facing an exciting growth journey.

2023-03-17

FinVoices: Henrik Wagenius on the new launch of Eucaps

Henrik Wagenius, founder and CEO of Eucaps, visits FinVoices to talk about the new launch of Eucaps - a digital platform that makes it easy for listed companies and investors around Europe to find each other.

The platform creates conditions for innovation and growth for both listed companies and investors.

2023-03-10

Impala Nordics co-founder, Aya Salar is interviewed by SAVR

Aya Salar is interviewed by SAVR where she talks about how she managed to create her own community, in which she developed her financial interest and self-confidence.

Watch the full video interview

2023-03-08

Correction: International Women's Day is a Mystery

Isabella Wulff, Digital Design and Marketing Communicator at Impala Nordic writes a column about International Women's Day.

She questions why this day is still needed to remind us that women and men are equally valuable.

2023-03-01

Film interview with CEO of MEEW A/S, Armin Kavousi

Armin Kavousi, CEO of MeeW A/S is interviewed by Impala Nordic and talks about MeeW's impressive growth journey and how they will continue to expand after the company is listed on the Spotlight Stock Market.

Watch the full video interview

2023-02-28

Hot chair - Blick Global Group AB

Erik Ahlberg, CEO of Blick Global Group AB, talks about the company's strong Q4 results with 160% growth and higher profit margins.

Erik shares the company's annual growth targets to be achieved through expansion, increased profitability and a continued clear pipeline for more acquisitions.

2023-02-23

Impala Nordic recruits Vilhelm Ruhr as Junior Analyst

Impala Nordic is expanding its team and recruiting Vilhelm Ruhr as Junior Analyst to Impala Nordic.

"Despite his young age, we have seen a strong ability in how Vilhelm analyzes companies and I am convinced that he will do a fantastic job at us" - Ylber Rexhepi.

2023-02-21

Hot chair: Interview with MeeW A/S

Armin Kavousi, CEO at MeeW A/S, talks about the company's business model and how it has grown fast in a short time.

MeeW conducts a new share issue in connection with an IPO and Armin thereby tells us how the issue proceeds will be used to internationalize MeeW.

2023-02-13

Chronicle: The Revolution in Medtech - An important part of ours future

Ylber Rexhepi, CEO of Impala Nordic writes a column about Medtech and its impact on society.

He also talks about future investment opportunities within Medtech and what to consider before such investments.

2023-02-10

FinVoices: Jenny Westergård from about emotional intelligence, EQ

Jenny Westergård, CEO of EQEurope visits Finvoices to introduce us to the concept of EQ, emotional intelligence.

Jenny has many years of experience in the financial industry and in leadership and works actively to convey the importance of companies measuring EQ among their management and its employees.

2023-01-26

Isabella Wulff - Digital design and marketing communicator

Impala Nordic expands the team and brings in Isabella Wulff as Digital Design and Marketing Communicator.

"A few days have passed and we can already see what a top candidate Isabella is, she is super creative and has quickly added value to us" - Aya Salar.

2023-01-18

FinVoices: Erik Ahlberg on Blick Globals recent acquisitions, key milestones and upcoming pipeline

Erik Ahlberg, CEO of Blick Global Group, is interviewed in FinVoices to provide an insight into the business, talk about the company's hopes for the future and share Blick Global's acquisition strategy.

2023-01-18

Guest Column: Set your investment strategy for 2023!

Joanna Törngren Redebrant writes a guest column at Impala Nordic to tell about her thoughts on her investment strategy for 2023 and which asset classes she will focus on.

2023-01-16

Hot chair: Interview with Spermosens

Ulrik Nilsson, CEO at Spermosens AB (publ), talks about the product JUNO-Checked System, the company's current collaboration agreements and what the upcoming issue proceeds will be used for

2023-01-13

Film interview with CEO of Blick Global Group, Erik Ahlberg

Erik Ahlberg, CEO of Blick Global Group AB, is interviewed by Impala Nordic and talks about where the company stands today, what the plan is going forward, how the latest acquisition affects the business and what the latest issue proceeds will be used for.

Watch the full video interview

2023-01-09

FinVoices: Christoffer Ahnemark on Nordic small companies

The fund manager at Origo Fonder talks about the fund portfolio and raises an investment case.

He explains the pros and cons of investing in under-analyzed companies and why they focus on Nordic small companies.

2022-12-21

FinVoices: Pär Rylöv guests FinVoices

He is a business development specialist at Connect Sweden and talks about how investments differ between listed and unlisted companies and what key factors investors should monitor in unlisted companies.

2022-12-20

The hot chair: Interview with Plexian

Fredrik Knutsson, vice president and commercialization manager at Plexian, talks about what the upcoming issue proceeds will be used for and about his area of responsibility to take the Edge platform to the market.

2022-12-15

Christmas competition on Instagram

Where does OMXS30 stand as of December 30, 2022? The competition takes place on our Instagram @impalanordic with the opportunity to win 2,000 SEK in a gift card of your choice.

All competition terms and conditions can be read on our Instagram account

To the competition

2022-11-30

Martin Wickström visits FinVoices

Martin Wickström, CEO of the Erik Olsson real estate agency, talks about his view on the real estate market, why he is not worried about future price adjustments and whether it is an attractive time to invest in real estate.

2022-11-24

The Hot Chair: Interview with Episurf Medical

Pål Ryfors, CEO of Episurf Medical, looks towards 2023 and has his sights set on the US market and the commercialization of Episealer.

2022-11-22

FinVoices: Jonas Olavi guest podcast

Jonas Olavi, fund manager and allocation manager at Alpcot AB, talks about his investment philosophy, stocks he has picked up recently and which companies to invest in when the stock market turns.

2022-11-18

Realtid interviews Impala Nordic

Impala Nordic is highlighted in Realtid where the founders explain why company analyses will be prepared without target prices and what distinguishes Impala Nordic from similar players.

2022-11-10

FinVoices: Sharon Lavie guest podcast

Sharon Lavie, savings economist at SAVR, will be the first person to guest FinVoices. She talks about her view on the development of inflation and why she sees an attractive stock market situation right now.

2022-11-10

The Hot Chair: Interview with BioArctic

Oskar Bosson, Investor Relations & Communications at BioArctic, talks about BioArctic's impressive progress, the partnership with Eisai and the great interest in the drug candidate Lecanemab.

2022-11-10

We are on Social Media

We are now on LinkedIn, Twitter, Instagram and Facebook. We are active and update frequently, follow us!